ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting

About this update from Immunitybio, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/8a3eaebe747535ea4b40d60f7e59be9c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zcU2Sc.9OQa31.Ia2mhxXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MA--/https://media.zenfs.com/en/business-wire.com/8a3eaebe747535ea4b40d60f7e59be9c","width":480,"height":270}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide important context, particularly in the absence of head-to-head data, highlighting its efficacy, durability, and safety in patients with CIS ± papillary disease and informing treatment selection and sequencing within current paradigms","length":333,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Exploration of intravesical recombinant BCG (rBCG) in BCG-naïve patients points to continued innovation and potential expansion into earlier lines of care","length":154,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Updates on company’s efforts to expand BCG access and on the status of randomized controlled BCG Naïve registrational trial","length":123,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":610,"olType":false},{"type":"text","content":"CULVER CITY, Calif., May 05, 2026--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it will present new treatment comparison results evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) versus nadofaragene firadenovec-vncg and TAR-200 in patients with non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), with or without papillary disease, at the American Urological Association Annual Meeting (AUA 2026) in Washington, DC, May 15-18. An additional oral presentation will include new insights into research of intravesical recombinant BCG (rBCG) in BCG-naïve patients.","length":680,"tagName":"p"},{"type":"text","content":"These analyses are clinically relevant for urologists managing an increasingly complex NMIBC treatment landscape, particularly among patients with BCG-unresponsive disease. In the context of limited d...

More updates from Immunitybio, Inc.